Advertisement

Topics

Innovative Biologics, Inc. Company Profile

02:07 EST 12th December 2018 | BioPortfolio

Innovative Biologics was established in December, 2003 and its research is supported by the NIH SBIR Phase II grant “Small molecule blockers of B. anthracis toxin.” Our company is located on the Prince Williams campus of George Mason University.
Our focus is to search for new anti-microbial drugs targeting bacterial toxins.

Location

10900 University BlvdMSN 1A8, Discovery Hall, Room 160
Manassas
Virginia
20110
United States of America

Contact

Phone: (703) 993-8544
Fax: (703) 993-8982
Email: info@innovbio.com


News Articles [604 Associated News Articles listed on BioPortfolio]

DSM Biologics: Karen King on New Technology and Reducing the Cost of Medicines

In this episode of PharmaTelevision News Review, Fintan Walton talks with Karen King, President and Business Unit Director of DSM Biologics. Filmed at BioChicago 2010 in Chicago, USA, they discuss: ...

WuXi Biologics to Invest $60 Million to Establish a Biologics Production Facility in the United ...

WuXi Biologics is a leading global platform company providing end-to-end solutions for biologics with a mission to accelerate and transform biologics discovery, development and manufacturing Read ...

Mike Riley, Catalent Biologics: Integrated solutions, better treatments.

Biologic therapies are transforming the treatment of disease and improving the lives of millions. Catalent Biologics partners with leading biologic and biosimilar developers on their next generation o...

WuXi Biologics' Chief Quality Officer Received Foreign Post Service Award from FDA

SHANGHAI, Sept. 17, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development...

WuXi Biologics Announced Exclusive Discovery Research with Brii Biosciences for Novel ...

SHANGHAI, Dec. 9, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development a...

WuXi Biologics Commenced Construction of the Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland

SHANGHAI and DUNDALK, Ireland, Dec. 5, 2018 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics...

Key Biologics merges with Astarte Biologics

In conjunction with the merger the new entity also received an investment from Ampersand Capital Partners to continue expanding the company in the rapidly evolving cell and gene therapy The post Key...

WuXi Biologics partners with Inhibrx for GMP manufacturing of protein─based therapeutics

WuXi Biologics, a leading global open─access biologics technology platform company offering end─to─end solutions for biologics discovery, development and manufacturing, and Inhibrx, Inc, a bioph...

PubMed Articles [336 Associated PubMed Articles listed on BioPortfolio]

Considerations for implementing an informatics system to support biologics drug discovery.

A comprehensive, well-functioning and scientifically aware informatics environment is of the utmost importance in supporting effective drug discovery programs. However, implementing such a system can,...

Advanced formulations for Intranasal Delivery of Biologics.

The global biologics market has been ever increasing over the last decades and is predicted to top Euro 350 by 2020. Facing this scenario, the parenteral route of biologics administration as hitherto ...

Persistence of treatment with biologics for patients with psoriasis: a real-world analysis of 16,545 biologic-naïve patients from the French national health insurance database (SNIIRAM).

Long-term clinical effectiveness of biologics in psoriasis is needed.

Biologics Monitoring: Incongruity between Recommendations and Clinician Monitoring Trends.

Biologics are a commonly used treatment for moderate to severe psoriasis. Monitoring laboratory test overuse provide little definitive benefit to patients.

Dose Increase beyond Labelled Dose of Biologics Is Associated With Incremental Pharmacy Costs: Results from a Real-World Study In the UK.

Evidence regarding dosing patterns of biologics among moderate to severe psoriasis patients and impact on costs in the United Kingdom (UK) is limited.

Clinical Trials [757 Associated Clinical Trials listed on BioPortfolio]

A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA)

The purpose of this study is to compare the efficacy of Biologics + Methotrexate with Biologics + Tacrolimus measured by the disease activity score 28 (DAS28) erythrocyte sedimentation rat...

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

The patients included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health plan...

Golimumab Safety and Surveillance Program Using the Ingenix NHI Database

The participants included in this observational study will be drawn from a research database containing claims and enrollment data for members of a large, geographically diverse US health ...

Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease

"RUN-CD" is an investigator initiated "Non interventional Trial" on biologics in Crohn´s Disease (CD) patients in Germany with a prospective documentation of effectiveness in induction an...

Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity

Rationale/hypothesis: Moderate-to-severe psoriasis can be treated with biologics. Objective To investigate whether the dose of biologics can be reduced in patients with psoriasis with sta...

Companies [519 Associated Companies listed on BioPortfolio]

Innovative Biologics, Inc.

Innovative Biologics was established in December, 2003 and its research is supported by the NIH SBIR Phase II grant “Small molecule blockers of B. anthracis toxin.” Our company is located on the ...

GT Biologics

GT Biologics is focused on the research and development of Live Biotherapeutics (LBPs) for the treatment of autoimmune diseases. GT Biologics aim to deliver a new class of medicine based on the po...

Precision Biologics Inc.

Founded in February 2012 and commencing business in late September 2012, Precision Biologics, Inc. is a clinical stage biotechnology corporation focused on developing therapeutic ...

ABEC and WuXi Biologics

WuXi Biologics, a Hong Kong-listed company, is the only open-access biologics technology platform in the world offering end-to-end solutions to empower organizations to discover d...

Burst Biologics

Burst Biologics is a rapidly growing Biotechnology Company and federally registered tissue bank located in Boise, Idaho. Burst Biologics is a developer of effective tissue process...

More Information about "Innovative Biologics, Inc." on BioPortfolio

We have published hundreds of Innovative Biologics, Inc. news stories on BioPortfolio along with dozens of Innovative Biologics, Inc. Clinical Trials and PubMed Articles about Innovative Biologics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Innovative Biologics, Inc. Companies in our database. You can also find out about relevant Innovative Biologics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...


Corporate Database Quicklinks



Searches Linking to this Company Record